araag2/HINT huggingface dataset:
Clinical trial NCT03638258 (phase 2, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: arq-151 cream 0.3%, arq-151 cream 0.15%, arq-151 vehicle cream
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Participants legally competent to sign and give informed consent

          -  Males and females ages 18 years and older (inclusive)

          -  Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined
             by the Investigator

          -  Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at
             Screening (Visit 1) and Baseline (Visit 2). In addition, sexually active FOCBP must
             agree to use at least one form of highly effective contraception throughout the trial.

          -  In good health as judged by the Investigator, based on medical history, physical
             examination, serum chemistry labs, hematology values, and urinalysis.

          -  Subjects are considered reliable and capable of adhering to the Protocol and visit
             schedule, according to the judgment of the Investigator.

        Exclusion Criteria:

          -  Planned excessive exposure of treated area(s) to either natural or artificial sunlight
             or tanning bed.

          -  Females who are pregnant, wishing to become pregnant during the study, or are
             breast-feeding.

          -  Previous treatment with ARQ-151 or its active ingredient

          -  Subjects with any serious medical condition or laboratory abnormality that would
             prevent study participation or place the subject at significant risk, as determined by
             the Investigator.

          -  Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation
             of study medication.

          -  Subjects who are unable to communicate, read or understand the local language, or who
             display another condition, which in the Investigator's opinion, makes them unsuitable
             for clinical study participation.
Clinical trial NCT03639987 (phase 2, status: terminated)
Conditions: cognitive dysfunction, alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: aducanumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study was discontinued based on futility analysis conducted on phase 3 trials (nct02477800 and
    nct02484547) and not based on safety concerns.
  
Eligibility criteria:

        Inclusion/ Exclusion Criteria

        Key Inclusion Criteria:

          -  Ability of the participant or his/her legally authorized representative to understand
             the purpose and risks of the study and provide signed and dated informed consent and
             authorization to use confidential health information in accordance with national and
             local participant privacy regulations.

          -  Must have at least 6 years of education or work experience to exclude mental deficits
             other than MCI due to AD or mild AD dementia.

          -  Must have evidence of cerebral Aβ accumulation, based on a positive PET scan of the
             brain. Previously obtained positron emission tomography (PET) scan (within 12 months
             of screening) is permissible. Previous PET scan images must be submitted to the
             central imaging vendor to confirm that study inclusion criteria are met.

          -  Must consent to apolipoprotein E (ApoE) genotyping.

          -  Must meet all of the following clinical criteria for MCI due to AD or mild AD dementia
             according to NIA-AA criteria [Albert 2011; McKhann 2011], and must have the following:
             MCI due to AD (a CDR global score of 0.5, and an MMSE score between 24 and 30
             (inclusive)), or Mild AD dementia (a CDR global score of 0.5 or 1, and as MMSE score
             between 20 and 26 (inclusive)).

        Key Exclusion Criteria:

          -  Any uncontrolled medical or neurological/neurodegenerative condition (other than AD)
             that, in the opinion of the Investigator, might be a contributing cause of the
             participant's cognitive impairment (e.g., substance abuse, vitamin B12 deficiency,
             abnormal thyroid function, stroke or other cerebrovascular condition, Lewy body
             dementia, frontotemporal dementia, head trauma).

          -  Clinically significant unstable psychiatric illness (e.g., uncontrolled major
             depression, uncontrolled schizophrenia, uncontrolled bipolar affective disorder)
             within 6 months prior to Screening.

          -  Transient ischemic attack or stroke or any unexplained loss of consciousness within 1
             year prior to Screening.

          -  Vaccinations within 10 days prior to randomization (Day 1).

          -  Female participants who are pregnant or currently breastfeeding.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Clinical trial NCT03657797 (phase 2, status: completed)
Conditions: glaucoma, open-angle, hypertension, ocular
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131
Drugs: ncx 470, latanoprost 0.005%
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of open-angle glaucoma or ocular hypertension in both eyes

          -  Qualifying IOP at 3 time points throughout the day at 2 visits following washout of
             IOP-lowering medication, if applicable

          -  Qualifying best-corrected visual acuity (BCVA) using the Early Treatment of Diabetic
             Retinopathy Study (ETDRS) protocol in each eye

          -  Ability to provide informed consent and follow study instructions

        Exclusion Criteria:

          -  Pigmentary or pseudoexfoliative glaucoma

          -  Narrow anterior chamber angles or disqualifying corneal thickness in either eye

          -  Clinically significant ocular disease in either eye

          -  Previous complicated surgery or certain types of glaucoma surgery in either eye

          -  Incisional ocular surgery or severe trauma in either eye within the past 6 months

          -  Uncontrolled systemic disease
Clinical trial NCT03676231 (phase 2, status: terminated)
Conditions: nonalcoholic steatohepatitis
ICD codes: K75.81
Drugs: sgm-1019, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study terminated due to a safety event which rendered the risk-benefit profile in nash to no
    longer be adequately favorable
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female

          -  Age 18 to 75 years, inclusive

          -  Elevated ALT

          -  F1-F3 NASH

          -  BMI ≥ 25

        Exclusion Criteria:

          -  Use of prohibited medication/supplements

          -  Poorly controlled type 2 diabetes

          -  Hepatic decompensation

          -  Chronic liver disease

          -  Planned surgeries/procedures
Clinical trial NCT03680612 (phase 2, status: completed)
Conditions: urinary tract infections
ICD codes: P39.3, N39.0, O86.20, O86.29, N99.531, O03.38, N99.521
Drugs: cefepime 1g - 2g / aai101 0.5g - 0.75g, cefepime 1 g or cefepime 2 g
SMILES: CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1, CO\N=C(/C(=O)N[C@@H]1C(=O)N2[C@]1([H])SCC(C[N+]1(C)CCCC1)=C2C([O-])=O)C1=CSC(N)=N1
Eligibility criteria:

        Inclusion criteria:

        • Male or female patients with clinical signs and/or symptoms of cUTI or acute
        pyelonephritis that were expected to require hospitalization and initial treatment with at
        least 7 days of i.v.

        antibiotics.

        Exclusion criteria:

          -  Patients with concurrent infection that would interfere with evaluation of response to
             the study antibiotics;

          -  Patients needing concomitant systemic antimicrobial agents in addition to those
             designated in the various study treatment groups;

          -  Patients receiving effective antibacterial drug therapy for any indication for a
             continuous duration of >24 hours during the previous 72 hours before the
             study-qualifying baseline urine was obtained or receiving any amount of potentially
             therapeutic antibacterial therapy after collection of the pre-treatment baseline urine
             culture and before administration of the first dose of study drug;

          -  Patients likely to require the use of an antibiotic for cUTI or acute pyelonephritis
             prophylaxis during participation in the study;

          -  Patients with confirmed fungal urinary tract infection at the screening visit (with
             ≥103 fungal colony forming units [CFU]/mL); or

          -  Patients with intractable urinary infection at baseline that the Investigator
             anticipated would require >10 days of study drug therapy were excluded from
             participation
Clinical trial NCT03702803 (phase 2, status: recruiting)
Conditions: generalized anxiety disorder
ICD codes: F41.1
Drugs: alprazolam 1mg
SMILES: CC1=NN=C2CN=C(C3=CC=CC=C3)C3=C(C=CC(Cl)=C3)N12
Eligibility criteria:

        Inclusion Criteria:

          -  Patients of both sexes

          -  Eighteen years of age and older

          -  Clinical diagnosis of Generalized Anxiety Disorder

          -  Eighteen points or more on Hamilton Anxiety Scale

          -  Without previous treatment for this disease (for at least one month before).

          -  In case of being women of reproductive age, who are not pregnant or lactating.

          -  To sign an informed consent letter of participation in the investigation.

        Exclusion Criteria:

          -  Patients who have treatment for their condition

          -  Patients who have another mental disorder added

          -  Patients with alcoholism, smoking or drug addiction

          -  Patients who live alone

          -  Ingest of drugs for insomnia

          -  Ingest of drugs of the Monoamine Oxidase Inhibitors group

          -  Patients with epilepsy

          -  Patients who operate dangerous machinery

          -  Patients who have to drive at work (car, truck or other motor vehicle) for a long
             time.
Clinical trial NCT03713320 (phase 2, status: terminated)
Conditions: cutaneous t-cell lymphoma/mycosis fungoides
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cobomarsen, vorinostat
SMILES: ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1
Reason stopped: 
    the study was terminated early for business reasons, and not due to concerns regarding safety
    or lack of efficacy.
  
Eligibility criteria:

        Key Inclusion Criteria:

          -  Biopsy-proven CTCL, MF subtype

          -  Clinical stage IB, II, or III, with staging based on screening assessments

          -  Minimum mSWAT score of 10 at screening

          -  Receipt of at least one prior therapy for CTCL

        Key Exclusion Criteria:

          -  Previous enrollment in a cobomarsen study

          -  Prior therapy with vorinostat or other HDAC inhibitors, or contraindication to an HDAC
             inhibitor

          -  Sézary syndrome or mycosis fungoides with B2 involvement, defined as documented
             history of B2 and/or B2 staging at screening

          -  Evidence of large cell transformation

          -  Lymph node involvement at screening, unless radiologically or histologically confirmed
             to be nonmalignant

          -  Visceral involvement related to MF at screening
Clinical trial NCT03715023 (phase 2, status: terminated)
Conditions: respiratory syncytial virus infections
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: pc786, placebo, soc
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    practical issues that could not be resolved resulting in recruitment difficulties at sites.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Received an allogeneic or autologous hematopoietic stem cell transplant (HSCT) using
             any conditioning regimen

          -  Experienced new onset of at least one of the following respiratory symptoms ≤5 days
             before study Day 1:

        Nasal congestion or stuffiness, runny nose (rhinorrhoea), cough, or sore throat OR
        Worsening of at least one of those symptoms, if symptoms are chronic OR Wheezing, sputum
        production, pleuritic chest pain, increased respiratory rate, signs on chest auscultation,
        hypoxia, increased supplemental oxygen requirement or new infiltrates on chest X-ray/CT

          -  A positive RSV diagnostic test

          -  Provided written informed consent

        Exclusion Criteria:

          -  Is intubated and requires invasive ventilation

          -  Has received any investigational RSV vaccine after HSCT, or has received any
             monoclonal anti-RSV antibodies within 4 months or 5 half-lives before participation

          -  Treatment with intravenous ribavirin

          -  Positive for test for influenza or parainfluenza

          -  Significant untreated bacteraemia or fungaemia

          -  Significant untreated bacterial, fungal, or viral pneumonia

          -  Precluded from participating as a result of treatment with another investigational
             drug or participation in another clinical trial

          -  Other disease or condition which would preclude the subject's participation in a
             clinical trial

          -  Is receiving an antiretroviral protease inhibitor

          -  Has chronic, active hepatitis infection

          -  Known alcohol or drug abuse
Clinical trial NCT03716050 (phase 2/phase 3, status: terminated)
Conditions: perfusion; complications
ICD codes: A36.89, B01.89, B02.9, B05.89, B06.89, B26.89, K94.30
Drugs: nitroglycerin
SMILES: COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1
Reason stopped: 
    pi decision due to slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must be female.

          -  Patients must be between the ages of 18 and 99 years.

          -  Patients must undergo mastectomy with our attending breast oncology surgeons followed
             by possible implant-based immediate breast reconstruction (IBR) performed by our
             attending plastic surgeons at WFBMC.

          -  Patients must have the ability to understand and the willingness to sign an
             IRB-approved informed consent document.

        Exclusion Criteria:

          -  Patients who are under the age of 18 or over the age of 99.

          -  Patients who are undergoing mastectomy without immediate breast reconstruction
             including immediate breast reconstruction with autologous tissue (or combination of
             autologous tissue with tissue expanders or implants), or patients with a history of
             mastectomy presenting for delayed breast reconstruction.

          -  Patients with pre-existing conditions in which use of indocyanine-green is
             contraindicated or must be used with caution, including those with a history of
             allergy to iodides or iodinated dye, those with chronic kidney disease, those with
             hepatic failure or cirrhosis of the liver, and females who are nursing, pregnant, or
             may become pregnant.

          -  Pregnant women are excluded from this study because pregnancy precludes immediate
             breast reconstruction in our patient population.

          -  Patients with pre-existing conditions in which use of nitroglycerin paste is
             contraindicated, including those with a history of cardiac insufficiency, hypotension,
             sensitivity to nitrites, severe liver impairment, glaucoma, hyperthyroidism, recent
             head trauma, severe anemia, or taking certain medication (i.e. alteplase, aspirin,
             beta-blocker, calcium channel blocker, diuretics or thiazides).

          -  Patients with pre-existing conditions in whom use of incisional negative pressure
             wound therapy is contraindicated including those with evidence of surgical site
             infection ( i.e. erythema, purulent drainage), clinical signs of hematoma (i.e. wound
             swelling, fluctuance, blood drainage), history of persistent cancer, exposed blood
             vessel on site of proposed therapeutic use, or sensitivity to acrylics and adhesives.
Clinical trial NCT03727607 (phase 2, status: completed)
Conditions: total intravenous anesthesia, desflurane, obesity, pain, postoperative, nausea, postoperative
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: desflurane
SMILES: FC(F)OC(F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  BMI ≥35 kg/m2 with at least one comorbid condition or BMI ≥40 kg/m2.

        Exclusion Criteria:

          -  drug abuse

          -  severe mental illness

          -  age<18

          -  serious medical condition; cancer, end-stage lung disease (ASA>3) or allergies to any
             drugs used in the study
Clinical trial NCT03732534 (phase 2, status: terminated)
Conditions: tourette syndrome
ICD codes: F95.2
Drugs: nbi-98854
SMILES: COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1
Reason stopped: 
    study stopped early due to investigational drug not meeting primary endpoint in the main study
    t-force gold (nbi-98854-ts2003); no safety concerns identified.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Have a clinical diagnosis of Tourette Syndrome (TS)

          2. Have participated in the NBI-98854-TS2004 or NBI 98854-TS2005 Phase 2 studies

          3. If using maintenance medication(s) for TS and/or TS spectrum diagnoses (e.g.
             obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]),
             be on stable doses

          4. Be in good general health

          5. Subjects of childbearing potential who do not practice total abstinence must agree to
             use hormonal or two forms of nonhormonal contraception (dual contraception)
             consistently during the screening, treatment and follow-up periods of the study

        Exclusion Criteria:

          1. Have an active, clinically significant unstable medical condition within 1 month
             before screening

          2. Have a known history of long QT syndrome or cardiac arrhythmia

          3. Have a known history of neuroleptic malignant syndrome

          4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)

          5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors

          6. Have a blood loss ≥250 mL or donated blood within 56 days, or donated plasma within 7
             days, before the start of the study

          7. Have a known history of substance dependence, substance (drug) or alcohol abuse within
             3 months before the start of the study

          8. Have a significant risk of suicidal or violent behavior

          9. Have received an investigational drug within 30 days before the start of the study or
             plan to use an investigational drug (other than NBI-98854) during the study

         10. Are currently participating in another NBI-98854 clinical study

         11. Are pregnant (for females)
Clinical trial NCT03824704 (phase 2, status: terminated)
Conditions: epithelial ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, high grade serous carcinoma, endometrioid adenocarcinoma
ICD codes: H18.523, H18.521, H18.522, H18.529, C57.00, C57.01, C57.02, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: rucaparib, nivolumab
SMILES: CNCC1=CC=C(C=C1)C1=C2CCNC(=O)C3=C2C(N1)=CC(F)=C3, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    sponsor made a business decision to discontinue the study due to low accrual.
  
Eligibility criteria:

        General Inclusion Criteria:

          -  ≥ 18 years of age

          -  Adequate organ function

          -  Life expectancy ≥ 16 weeks

          -  Women of childbearing potential must have a negative serum pregnancy test

          -  High-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary
             peritoneal cancer

          -  Received 1 or 2 prior regimens, including ≥ 1 prior platinum-based therapy and have
             platinum-sensitive disease

          -  Relapsed/progressive disease (confirmed by radiologic assessment)

          -  Willing and able to have a biopsy of tumor at screening and after 4 weeks of
             treatment.

          -  Measurable disease (RECIST v1.1)- Cohort A1 only

          -  ECOG performance status of 0 to 1

        General Exclusion Criteria

          -  Active second malignancy

          -  Central nervous system brain metastases

          -  Evidence of interstitial lung disease, active pneumonitis, myocarditis, or history of
             myocarditis.

          -  Active, known or suspected autoimmune disease (eg, autoimmune hepatitis).

          -  Condition requiring systemic treatment with either corticosteroids

          -  Prior treatment with a PARP inhibitor or immune checkpoint inhibitor.

          -  Non-epithelial tumors (pure sarcomas) or ovarian tumors with low malignant potential
             (ie, borderline tumors) or mucinous tumors. Mixed Mullerian tumors/carcinosarcomas are
             allowed.
Clinical trial NCT03831191 (phase 2, status: terminated)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: ly3375880, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study was terminated for lack of efficacy after an interim analysis was performed
  
Eligibility criteria:

        Inclusion Criteria:

          -  Participants must have diagnosis of AD >= 12 months according to the American Academy
             of Dermatology criteria.

          -  Participants must have moderate to severe AD at screening and randomization.

          -  Participants must have inadequate response to topical medications within 6 months of
             screening (or history of intolerance).

        Exclusion Criteria:

          -  Participants must not have concurrent treatment with topical or systemic treatments
             for AD.